Q4 2024 CeriBell Inc Earnings Call Transcript

Feb 25, 2025 / 09:30 PM GMT

Release Date Price: $25.54 (+0.43%)

Transcript 10-K8-K

Key Points

Positve

CeriBell Inc (CBLL) reported a 41% increase in Q4 2024 revenue, reaching $18.5 million, and a 45% increase for the full year, totaling $65.4 million.
The company achieved strong gross margins of 88% in Q4 and 87% for the full year 2024, reflecting efficient manufacturing processes.
CeriBell Inc (CBLL) expanded its active accounts to 529 by the end of 2024, with a strategic focus on targeting 5,500 remaining prospective accounts.
The company is investing in R&D to expand its product indications, including pediatric and neonate clarity algorithms, and has received FDA breakthrough device designation for delirium detection.
CeriBell Inc (CBLL) successfully completed an upsized IPO, raising approximately $188 million, which will be used to accelerate R&D and commercial expansion.

Negative

CeriBell Inc (CBLL) reported a net loss of $12.6 million for Q4 2024, an increase from the $8.3 million loss in Q4 2023.
Operating expenses increased by 49% in Q4 2024 compared to the same period in 2023, driven by investments in commercial organization and public company operations.
The company faces a 35% tariff on materials sourced from China, impacting its supply chain costs.
Stock-based compensation is expected to contribute approximately $15 million to operating expenses in 2025, reflecting increased costs as a public company.
The transition to operating as a public company has increased legal, accounting, and professional service fees, contributing to higher operating expenses.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

CBLL.OQ - CeriBell Inc
Q4 2024 CeriBell Inc Earnings Call
Feb 25, 2025 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Hello and thank you for standing by. At this time, I would like to welcome you to the Cerebell Q4 2024 earnings call. All lines have been placed on view to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press start, followed by the number one on your telephone keypad.

If you would like to withdraw your question, press start one again.

I would now like to turn the conference over to Brian Johnson, investor relations. Please go ahead, sir.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.